The 38th China Pharmaceutical Industry Information Annual Conference 2021 and the Release of Top 100 Pharmaceutical Companies in China 2020 were held, in which Mabwell was successfully included in the "List of New and Innovative Chinese Pharmaceutical Forces 2021" by virtue of its excellent innovation and R&D strength.

Innovation is the first driving force to lead development. Only reformers can advance, only innovators are strong, and only those who are both reformers and innovators can win. With the further promotion of "innovation-driven development strategy" and "healthy China strategy" in China, the innovative force is becoming the core momentum to escort the physical and mental health of the Chinese people. From 2020, the China National Pharmaceutical Industry Information Center, as the organizer of the China Pharmaceutical Industry Information Annual Conference 2021, together with the China State Institute of Pharmaceutical Industry and the Shanghai Institute of Pharmaceutical Industry, has formed an expert evaluation team to research and analyze new and innovative pharmaceutical companies in China based on objective data. It was the first time to release the List of New and Innovative Chinese Pharmaceutical Forces. In 2021, the above authorities have researched and analyzed the pharmaceutical companies based on objective data and released the List of New and Innovative Chinese Pharmaceutical Forces 2021.

Evaluation Rationale for List

Data source: New drug R&D monitoring database and review of application data from companies.
Evaluation basis: Evaluation is performed at two levels: products and companies. The innovation dimension, investment dimension, technology dimension and competition dimension will be investigated at the product level; the characteristics dimension, momentum dimension, strategy dimension and development dimension will be investigated at the company level. The review team will score each company from each dimension.
Evaluation and scoring: Two independent expert teams, i.e. the product evaluation team and the company evaluation team, will establish the scoring criteria for several dimensions of the drug and the company, respectively; the experts from the comprehensive evaluation team will apply a factor to adjust the weight of the proportion of each dimension in comprehensive evaluation, and multiply the factor with the standard score. The comprehensive score of the company will be obtained after weighted calculation. The final ranking of the company is determined by the comprehensive score.

This award is an affirmation of Mabwell's biotechnology advances, innovation capabilities, R&D investment and company competitiveness. Mabwell has five international leading technology platforms: automated and high throughput new hybridoma antibody molecule discovery platform, efficient B-lymphocyte screening platform, ADC drug development platform, PEG modification technology platform, and bispecific/bifunctional antibody development platform. Mabwell always upholds the vision of "transforming innovation from dream to reality", and practices the mission of "exploring life and benefiting health". Through source innovation and the whole industry chain layout, Mabwell is intended to provide biologically innovative drugs with better efficacy and better accessibility for patients in order to meet the unmet clinical needs throughout the world.